Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain.

Abstract

BACKGROUND Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action: µ-opioid receptor agonism and norepinephrine reuptake inhibition. This randomized, open-label phase 3 study (ClinicalTrials.gov Identifier: NCT00361504) assessed the long-term safety and tolerability of tapentadol extended release (ER) in patients with chronic knee or… (More)
DOI: 10.1111/j.1533-2500.2010.00397.x

Topics

6 Figures and Tables

Slides referencing similar topics